MedTrace Logo

Death to Onchocerciasis and Lymphatic Filariasis (DOLF) Triple Drug Therapy for Lymphatic Filariasis

NCT02899936 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 23789

Last updated 2020-12-31

No results posted yet for this study

Summary

The DOLF Triple Drug Therapy for Lymphatic Filariasis study will determine the frequency, type and severity of adverse events following triple-drug therapy (IVM+DEC+ALB, IDA) compared to the standard two-drug treatment (DEC+ALB, DA) in infected and uninfected individuals in a community in 5 different countries. The objective is to acquire safety, efficacy, and acceptability data to assess the safety and acceptability of the IDA drug combination.

Conditions

  • Lymphatic Filariasis

Interventions

DRUG

3 drug dose - IDA

Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA)

DRUG

2 drug dose - DA

Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine, and albendazole (DA)

Sponsors & Collaborators

  • Case Western Reserve University

    collaborator OTHER

  • Indian Council of Medical Research

    collaborator OTHER_GOV

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Gary Weil, MD · Washington University School of Medicine

  • Christopher King, MD PHD · Case Western Reserve University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2017-04-27
Completion
2018-05-31

Countries

  • Haiti
  • India
  • Indonesia
  • Papua New Guinea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02899936 on ClinicalTrials.gov